))
S4 E3 - Courtney DiNardo, MD MSCE – Perspectives on AML
Manage episode 407348217 series 3559566
Content provided by Karger Publishers. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Karger Publishers or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
This is the third episode in our series on myelodysplastic syndromes (MDS) which aims to update clinicians on the latest developments in their diagnosis and management.
In this episode, Dr. DiNardo discusses the missing pieces of MDS management, starting with the latest approvals in MDS treatment and how eligibility for clinical trials is assessed. She also touches on which impacts of transplantation or transformation to acute myeloid leukemia (AML) can be managed. She also touches on the cutting-edge genetic insights that might deliver on the promise of personalized medicine to MDS patients with the most challenging diagnoses.
For more podcast episodes from Karger please visit karger.com/podcasts.
This podcast was funded by Taiho Oncology, Inc. The faculty and publisher are solely responsible for this content. Taiho does not recommend or endorse the use of its products other than as described in the approved labeling. The content of this site is not medical advice and does not replace independent medical judgment.
17 episodes
Share
